Since when have they ever cared about their share price?
And as someone noted on iHub, wouldn't it have been a whole lot more effective to drop this suit before the JAMA article came out? Seems like that would have helped prevent the slide from $1.20 to $85. On the other hand, it also seems plausible they used the article release to set some kind of trap, specifically to collect more evidence prior to filing the suit. That's what I would have done, anyway.